Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Proteomic Approaches to Biomarker Discovery in Lung Cancers by SELDI Technology

[Application of Saliva Protein Fingerprints in the Diagnosis of Oral Squamous Cell Cancer by Surface Enhanced Laser Desorption Ionization Time of Flight Mass].

Development Of Proteomic Patterns For Detecting Lung Cancer

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

A Preliminary Analysis of Non-Small Cell Lung Cancer Biomarkers in Serum.

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

The study of lung adenocarcinoma serum biomarkers selected by surface-enhanced laser desorption ionization spectrometry

Application of Serum Surface-Enhanced Laser Desorption/ionization Proteomic Patterns in Distinguishing Lung Cancer Patients from Healthy People.

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Discovery of Laryngeal Carcinoma by Serum Proteomic Pattern Analysis

Biomarker Discovery and Identification from Non-Small Cell Lung Cancer Sera.

Identification of Serum Biomarkers for Lung Cancer Using Magnetic Bead-Based Seldi-Tof-Ms

Detection and Significance of Serum Protein Markers of Small-Cell Lung Cancer

Discovery of biomarkers related with lung adenocarcinoma metastasis using proteomics technique

Application of Liquid Chip-Mass Spectrometry Technology for Screening Serum Biomarker Proteins in Lung Squamous Cell Carcinoma

Proteomic Patterns in Serum of Lung Adenocarcinoma Patients and Its Correlation with Clinical TNM Stage

Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifying biomarkers of laryngeal carcinoma

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Clinical Significance of Biomarkers from Serum in Liver Cancer by SELDI-TOF Mass Spectrometry

Application of Laser Capture Microdissection and Surface-enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Biomarkers for Early Diagnosis of Lung Adenocarcinoma

Use of Anchorchip-Time-Of-Flight Spectrometry Technology to Screen Tumor Biomarker Proteins in Serum for Small Cell Lung Cancer